Suchergebnisse - "Zingman, Barry S"

PubPharm (80)

51

Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults

enthalten in: Antimicrobial agents and chemotherapy | 2010

von Jacobson, J. | Lalezari, J. | Thompson, M. | +10

52

Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults

enthalten in: Antimicrobial agents and chemotherapy | 2010

von Jacobson, J. | Lalezari, J. | Thompson, M. | +10

53

Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody

enthalten in: The Journal of infectious diseases | 2010

von Jacobson, J. | Thompson, M. | Lalezari, J. | +9

CommentIn: Curr HIV/AIDS Rep. 2011 Mar;8(1):1-3. - PMID 21170687

54

Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects : 48-week results of the VICTOR-E1 phase 2 trial

enthalten in: The Journal of infectious diseases | 2010

von Suleiman, J. | Zingman, B. | Diaz, R. | +8

CommentIn: J Infect Dis. 2011 Jan 15;203(2):292; author reply 293. - PMID 21288830

55

Vicriviroc in Combination Therapy with an Optimized Regimen for Treatment-Experienced Subjects: 48-Week Results of the VICTOR-E1 Phase 2 Trial

Erschienen: 2010

von Suleiman, J. | Zingman, B. | Diaz, R. | +8

56

Anti-HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140, a CCR5 Monoclonal Antibody

Erschienen: 2010

von Jacobson, J. | Thompson, M. | Lalezari, J. | +9

57

HIV/AIDS - Vicriviroc in Combination Therapy with an Optimized Regimen for Treatment-Experienced Subjects: 48-Week Results of the VICTOR-E1 Phase 2 Trial

enthalten in: The journal of infectious diseases | 2010

von Suleiman, J. | Zingman, B. | Sobhie Diaz, R. | +8

58

Anti-HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140, a CCR5 Monoclonal Antibody

enthalten in: The journal of infectious diseases | 2010

von Jacobson, J. | Thompson, M. | Lalezari, J. | +9

59

Occurrence of selective ritonavir nonadherence and dose-staggering in recipients of boosted HIV-1 protease inhibitor therapy

enthalten in: HIV clinical trials | 2009

von Shuter, J. | Sarlo, J. | Rode, R. | +1

60

Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults

enthalten in: The Journal of infectious diseases | 2008

von Jacobson, J. | Saag, M. | Thompson, M. | +20